Plasmapheresis for a Female with Cryptogenic New-Onset Refractory Status Epilepticus Not Benefiting from Monoclonal Antibody Therapy
- Author:
Hongmin HA
1
;
Young-Soo KIM
;
Do-Hyung KIM
;
Tae-Won YANG
;
Bora CHUNG
;
Chan Hyun LEE
;
Eunji KIM
;
Oh-Young KWON
Author Information
- Publication Type:Case Report
- From:Journal of the Korean Neurological Association 2022;40(2):176-180
- CountryRepublic of Korea
- Language:Korean
- Abstract: Monoclonal antibodies are pure antibodies that react to a specific epitope. Plasmapheresis is a treatment that separates and eliminates disease-causing substances before replacing the blood with plasma. Plasmapheresis has insufficient evidence for treating new-onset refractory status epilepticus (NORSE). Sequential plasmaphereses gradually improved a female cryptogenic NORSE patient who did not benefit from monoclonal antibody treatment.
